Table 1.
Patient characteristics.
| MPN-Ruxo | MPN-no Ruxo | p | HCs | |
|---|---|---|---|---|
| (n = 20) | (n = 54) | (n = 81) | ||
| Age, median (range) | 71.5 (41–85) | 73 (44–92) | 0.669 | 74 (55–92) |
| Sex, n, male (%) | 14 (70.0) | 25 (46.2) | 0.06 | 34 (42.0) |
| Diagnosis, n (%) | – | |||
| ET | 3 (15.0) | 29 (53.7) | NA | |
| PV | 3 (15.0) | 17 (31.5) | NA | |
| MF | 13 (65.0) | 6 (11.1) | <0.001 | |
| Primary MF/secondary MF | 6 (30.0)/7 (35.0) | 4 (7.4)/2 (3.7) | ||
| MPN-U | 1 (5.0) | 2 (3.7) | NA | |
| Time from diagnosis, years, | 6.7 (4.1–11.6) | 5.8 (2.8–9.4) | 0.642 | – |
| median (IQR) | ||||
| Driver mutation, n (%) | – | |||
| JAK2 | 11 (55.0) | 36 (66.7) | 0.41 | |
| CALR | 3 (15.0) | 8 (14.8) | NA | |
| MPL | 2 (10.0) | 0 (0) | NA | |
| Triple-negative | 3 (15.0) | 10 (18.5) | ||
| NA | 1 (5.0) | – | ||
| WBC (×103/μL), median (IQR) | 6.6 (3.6–9.7) | 6.3 (3.8–8.6) | 0.039 | NA |
| Lymphocyte (×103/μL), median (IQR) | 1.1 (0.9–1.6) | 1.4 (1.1–1.9) | 0.039 | NA |
| Treatment, n (%) | NA | – | ||
| Ruxolitinib | 20 (100) | – | ||
| Cytoreductive therapy | – | 34 (63.0) | ||
| No treatment | – | 20 (37.0) | ||
| Time of exposition to | NA | – | ||
| ruxolitinib, n (%) | ||||
| <1 year | 11 (55.0) | – | ||
| ≥1 year | 9 (45.0) | – | ||
| Dose of ruxolitinib, n (%) | NA | – | ||
| ≤20 mg | 13 (65.0) | – | ||
| >20 mg | 7 (35.0) | – | ||
| Interval from 2nd vaccine to | 42.5 (22.5–74.5) | 41.5 (27–64.75) | 0.642 | 41 (29–55) |
| Ab analysis, median (IQR) | ||||
| Anti-S Ab level, median (IQR) | 11.35 | 319.5 | <0.001 | 677 |
| (2.06–68.17) | (170.25–689.0) | (362–1,191) | ||
| Seroconversion, n (%) | 16 (80.0) | 52 (96.3) | 0.036 | 81 (100) |
| Achieving protective value, n (%) | 2 (10.0) | 31 (57.4) | <0.001 | 71 (87.6) |
| Anti-N antibody positivity, n (%) | 0 (0) | 0 (0) | 1 | 0 (0) |
MPN-Ruxo, myeloproliferative neoplasms with ruxolitinib; MPN-no Ruxo, myeloproliferative neoplasms without ruxolitinib; HCs, healthy controls; ET, essential thrombocythaemia; PV, polycythaemia vera; MF, myelofibrosis; MPN-U, myeloproliferative neoplasms, unclassifiable; JAK2, Janus kinase 2; CALR, calreticulin; MPL, thrombopoietin receptor; WBC, white blood cells; IQR, interquartile range; Anti-S Ab, anti-spike-receptor binding domain antibody; Anti-N IgG, anti-nucleocapsid protein IgG, NA: not assessed.